Effect of the XELOX or capecitabine monotherapy on patients with colorectal cancer and nursing
10.3760/cma.j.issn.1674-2907.2013.32.014
- VernacularTitle:XELOX 和卡培他滨单药口服治疗结直肠癌患者的效果比较及护理
- Author:
Shan-Shan XU
1
;
Xu-Dan WANG
;
Yue SUN
;
Xue LIANG
Author Information
1. 150086,哈尔滨医科大学附属二院结直肠肿瘤外科
- Keywords:
Colorectal cancer;
Hand-foot syndrome;
Nursing;
Capecitabine;
XELOX
- From:
Chinese Journal of Modern Nursing
2013;48(32):3985-3988
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the effect between oxaliplatin plus capecitabine (XELOX) and capecitabine monotherapy in the treatment of colorectal cancer (CRC) in patients, and explore the incidence rate and nursing of hand -foot syndrome (HFS).Methods Eighty patients with CRC were randomly divided into the XELOX group (n=50) and the monotherapy group (n=30) according to the random number table , and the overall survival (OS) and the incidence rate of HFS was compared between two groups .Results The median survival time were respectively 24.2 and 22.4 months in the XELOX and monotherapy group , and the overall survival rateswere respectively 78.0% and 76.7% in two groups, and the differences were not statistically significant (P>0.05).The incidence rates of HFS were respectively 34.0% and 60.0% in the XELOX and monotherapy group, and the difference was statistically significant (χ2 =8.8, P =0.02 ).Conclusions The effect of the XELOX or capecitabine monotherapy on patients with colorectal cancer is no significant difference;XELOX can reduce the incidence rate of HFS;the effective nursing of HFS can ensure the long-term medication of capecitabine .
